Relief Cardiovascular Announces $12M Series A Financing to Advance First-in-Human Study of the Relief System
IRVINE, Calif., Jan. 8, 2025 /PRNewswire/ — Relief Cardiovascular, an inQB8 Medical Technologies portfolio company pioneering innovative solutions for the management of heart failure, today announced the closing of a $12M Series A financing. The funding round was co-led by Broadview Ventures and Advent Life Sciences, with participation from Pacific Health Investment, Heartwork Capital, and an undisclosed multinational strategic. The funds will support further product development and the initiation of the company’s first-in-human feasibility study, designed to evaluate the safety and efficacy of the Relief System – a transcatheter smart implant designed to monitor and modulate renal vein pressures, offering a novel approach to fluid management in heart failure.
